Target Company Overview

Laboratoire Benewmedical is a distributor of innovative medical devices that offer significant medical-economic value. Initially established as a pure trading company, the organization has transitioned towards becoming a manufacturer, adopting an audacious and forward-thinking position in innovative surgical technologies, particularly in the field of regenerative surgery.

The company sources and negotiates distribution agreements, thus ensuring the market introduction of products for which it holds distribution mandates, as well as their quality and safety. Laboratoire Benewmedical offers approximately 800 references across three product divisions: regenerative surgery, general surgery, and outpatient services.

Industry Overview in France

The medical device industry in France is a vital sector characterized by rapid innovation and an increasing emphasis on higher quality healthcare solutions. France remains one of the world's largest markets for medical devices, underpinned by a strong investment in research and development. This positions the country as a significant player in the global market.

Moreover, French regulations support the continuous advancement of medical technologies, promoting the development of state-of-the-art surgical tools and devices. The growing elderly population and the rising incidence of chronic diseases further contribute to the demand for innovative medical solutions, driving growth in the industry.

In recent years, there has been a notable shift towards minimally invasive and regenerative surgical procedures, creating opportunities for companies focused on these areas. As demand rises, French companies are increasingly investing in new technologies and enhancing product offerings to meet evolving healthcare needs.

Rationale Behind the Deal

In 2023, Axio Capital executed a management buyout (MBO) of Laboratoire Benewmedical. The founder and principal shareholder aimed to divest his entire stake and facilitate a transfer of ownership to the company's two principal managers, Jérémy Glardon and Damien Bordier. Following the transaction, Axio Capital holds a 67.5% stake alongside the two managers, establishing a strong basis for future growth.

The ambition of the new ownership structure is to re-position Laboratoire Benewmedical as a leading manufacturer specializing in regenerative surgery, leveraging the company's robust growth potential in both the French market and internationally.

Investor Information

Axio Capital is a strategic investment firm known for its focus on the healthcare sector. Their expertise lies in identifying high-potential companies and driving the necessary changes to amplify growth and profitability. With a keen eye for innovation, Axio Capital supports initiatives that align with its objective to invest in transformative healthcare solutions.

By acquiring a substantial stake in Laboratoire Benewmedical, Axio Capital is well-positioned to help the company capitalize on emerging trends in regenerative medicine, thereby enhancing its market presence and facilitating the transition into a manufacturing role.

View of Dealert

The transaction between Axio Capital and Laboratoire Benewmedical presents a compelling investment opportunity. Given the strong market potential for innovative surgical technologies in France, the management team’s experience and vision contribute significantly to the investment’s attractiveness.

Furthermore, with the ongoing shift towards regenerative surgery and minimally invasive procedures, Laboratoire Benewmedical is strategically positioned to capture growth within this burgeoning sector.

However, the success of this investment will depend heavily on the execution of the company’s new strategic direction and its ability to innovate in a competitive landscape. If the management effectively leverages the existing distribution channels while transitioning into manufacturing, the company is likely to see substantial growth.

In conclusion, this MBO not only secures a promising future for Laboratoire Benewmedical but also aligns with Axio Capital’s strategy to invest in high-growth healthcare opportunities, making it a potentially lucrative investment.

View Original Article